Publication: Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: A meta-analysis
Issued Date
2019-04-01
Resource Type
ISSN
14735687
0954691X
0954691X
Other identifier(s)
2-s2.0-85062401151
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Gastroenterology and Hepatology. Vol.31, No.4 (2019), 514-519
Suggested Citation
Ronpichai Chokesuwattanaskul, Charat Thongprayoon, Tarun Bathini, Oisin A. O'Corragain, Konika Sharma, Somchai Preechawat, Karn Wijarnpreecha, Paul T. Kröner, Patompong Ungprasert, Wisit Cheungpasitporn Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: A meta-analysis. European Journal of Gastroenterology and Hepatology. Vol.31, No.4 (2019), 514-519. doi:10.1097/MEG.0000000000001315 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/51778
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Epidemiology of atrial fibrillation in patients with cirrhosis and clinical significance: A meta-analysis
Abstract
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved. Objective The epidemiology of atrial fibrillation (AF) in patients with cirrhosis and its clinical significance remain unclear. This study aimed (i) to investigate the pooled prevalence and/or incidence of AF in patients with cirrhosis and (ii) to assess the mortality risk of AF in patients with cirrhosis. Patients and methods A literature search for studies that reported incidence of AF in patients with cirrhosis was carried out using Medline, Embase, and Cochrane Database from inception through July 2018. Pooled incidence with 95% confidence interval (CI) was calculated using a random-effect model. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018102664). Results Seven cohort studies including 385 866 patients with cirrhosis were identified. The pooled estimated prevalence of AF in patients with cirrhosis was 5.0% (95% CI: 2.8-8.6%). When studies that solely assessed patients undergoing transplant evaluation or on transplant waiting list were excluded, the pooled estimated prevalence of AF in patients with cirrhosis was 7.4% (95% CI: 3.5-15.2%). There was a significant association between AF and increased mortality risk in cirrhotic patients with a pooled odds ratio of 1.44 (95% CI: 1.36-1.53). Conclusion The overall estimated prevalence of AF among patients with cirrhosis is 5.0%. Our study demonstrates a statistically significant increased mortality risk in cirrhotic patients with AF.